12:03 AM EDT, 07/14/2026 (MT Newswires) -- BioArctic (BIOA-B.ST) said its partner Eisai secured the US Food and Drug Administration's approval for Leqembi Iqlik subcutaneous injection as a once-weekly starting dose for the treatment of early Alzheimer's disease. The positive regulatory decision is based on a comprehensive clinical data package comprising multiple studies that showed the once-weekly subcutaneous injection worked as well as intravenous dosing, according to a Monday release. The approved initiation dose is 500 milligrams once weekly, delivered via two 250-milligram injections. Leqembi Iqlik, or lecanemab irmb, is expected to be launched in the US in late August.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.